# T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

> **NCT06045767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ari Raphael** · enrollment: 30 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Pembrolizumab 50 MG Injection [Keytruda]

## Key facts

- **NCT ID:** NCT06045767
- **Lead sponsor:** Ari Raphael
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045767, "T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06045767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*